Reduced high-sensitivity C-reactive protein levels following weekly somapacitan in adults with growth hormone deficiency: a prospective pilot study.

Serum hs-CRP levels significantly decreased following 6 months of weekly somapacitan therapy in adults with GHD.

• 13 adult patients with GHD were evaluated (9 men; 10 with adult-onset GHD)
• hs-CRP levels decreased from 0.24 [0.07–0.51] to 0.07 [0.06–0.25] mg/dL (P < .001)
• This was a prospective pilot study with a 6-month treatment duration
• Somapacitan was administered as a once-weekly GH derivative

Serum IGF-1 levels and IGF-1 SD scores significantly increased following somapacitan therapy.

• IGF-1 levels increased from 80 ± 53 to 148 ± 74 ng/mL (P < .001)
• IGF-1 SD scores increased from -2.8 ± 2.3 to -0.4 ± 1.7 (P < .001)
• These changes indicate successful GH replacement as reflected by normalization of IGF-1 toward age-appropriate levels

Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores, AST, and ALT.

• Changes in hs-CRP correlated with changes in IGF-1 SD scores (r = -.66, P = .01)
• Changes in hs-CRP correlated with changes in AST (r = .67, P = .01)
• Changes in hs-CRP correlated with changes in ALT (r = .74, P = .004)
• The negative correlation with IGF-1 SD scores indicates that greater IGF-1 increases were associated with greater hs-CRP reductions

Changes in hs-CRP levels remained significantly associated with ALT changes independent of IGF-1 SD score changes in partial correlation analyses.

• Partial correlation analysis showed hs-CRP changes remained associated with ALT changes (r = .59, P = .04)
• This association was independent of IGF-1 SD score changes
• This finding suggests a liver-mediated pathway for somapacitan's anti-inflammatory effects

AST and ALT levels showed slight but statistically insignificant decreases after somapacitan treatment.

• The decreases in AST and ALT did not reach statistical significance
• Despite non-significant changes in absolute liver enzyme levels, their changes correlated significantly with hs-CRP changes
• This pattern suggests liver involvement in mediating the inflammatory marker reduction